A Novel Strategy for Screening Active Components in <i>Cistanche tubulosa</i> Based on Spectrum-Effect Relationship Analysis and Network Pharmacology

<div>Venn diagrams of PLSR and BCA model: (a) DPPH assay. (b) <svg height="14.6307pt" id="M28" style="vertical-align:-3.834001pt" version="1.1" viewbox="-0.0498162 -10.7967 19.4427 14.6307" width="19.4427pt" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink"><g transform="matrix(.013,0,0,-0.013,0,0)"><path d="M381 665C170 665 44 498 44 318C44 125 188 -15 369 -15C552 -15 703 117 703 333C703 534 550 665 381 665ZM359 629C491 629 601 517 601 306C601 114 502 21 390 21C249 21 146 158 146 346S248 629 359 629Z"></path></g><g transform="matrix(.0091,0,0,-0.0091,9.711,-5.741)"><path d="M333 262C333 337 270 397 193 397S54 337 54 262S116 127 193 127S333 187 333 262Z"></path></g><g transform="matrix(.0091,0,0,-0.0091,13.214,-5.741)"><path d="M556 236V289H56V236H556Z"></path></g><g transform="matrix(.0091,0,0,-0.0091,9.711,3.784)"><path d="M414 144C384 79 371 75 317 75H135L276 221C367 316 408 376 408 465C408 570 327 635 237 635C179 635 131 609 100 575L42 494L67 471C94 510 138 565 205 565C277 565 321 517 321 435C321 348 258 270 195 195C146 137 88 81 33 26V0H411C423 44 433 88 446 135L414 144Z"></path></g></svg> scavenging assay. (c) <svg height="9.11633pt" id="M29" style="vertical-align:-0.3499298pt" version="1.1" viewbox="-0.0498162 -8.7664 24.566 9.11633" width="24.566pt" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink"><g transform="matrix(.013,0,0,-0.013,0,0)"><path d="M381 665C170 665 44 498 44 318C44 125 188 -15 369 -15C552 -15 703 117 703 333C703 534 550 665 381 665ZM359 629C491 629 601 517 601 306C601 114 502 21 390 21C249 21 146 158 146 346S248 629 359 629Z"></path></g><g transform="matrix(.013,0,0,-0.013,9.594,0)"><path d="M729 650H468V622C546 615 554 610 554 527V365H213V527C213 610 221 616 297 622V650H38V622C120 616 128 611 128 527V123C128 39 120 34 40 28V0H303V28C221 34 213 40 213 123V322H554V123C554 39 546 34 460 28V0H728V28C647 34 639 39 639 123V527C639 610 647 615 729 622V650Z"></path></g><g transform="matrix(.013,0,0,-0.013,19.552,0)"><path d="M320 255C320 327 260 385 186 385S52 327 52 255S112 125 186 125S320 183 320 255Z"></path></g></svg> scavenging assay were analyzed by the PLSR model. (d) DPPH assay. (e) <svg height="14.6307pt" id="M30" style="vertical-align:-3.834001pt" version="1.1" viewbox="-0.0498162 -10.7967 19.4427 14.6307" width="19.4427pt" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink"><g transform="matrix(.013,0,0,-0.013,0,0)"><path d="M381 665C170 665 44 498 44 318C44 125 188 -15 369 -15C552 -15 703 117 703 333C703 534 550 665 381 665ZM359 629C491 629 601 517 601 306C601 114 502 21 390 21C249 21 146 158 146 346S248 629 359 629Z"></path></g><g transform="matrix(.0091,0,0,-0.0091,9.711,-5.741)"><path d="M333 262C333 337 270 397 193 397S54 337 54 262S116 127 193 127S333 187 333 262Z"></path></g><g transform="matrix(.0091,0,0,-0.0091,13.214,-5.741)"><path d="M556 236V289H56V236H556Z"></path></g><g transform="matrix(.0091,0,0,-0.0091,9.711,3.784)"><path d="M414 144C384 79 371 75 317 75H135L276 221C367 316 408 376 408 465C408 570 327 635 237 635C179 635 131 609 100 575L42 494L67 471C94 510 138 565 205 565C277 565 321 517 321 435C321 348 258 270 195 195C146 137 88 81 33 26V0H411C423 44 433 88 446 135L414 144Z"></path></g></svg> scavenging assay. (f) <svg height="9.11633pt" id="M31" style="vertical-align:-0.3499298pt" version="1.1" viewbox="-0.0498162 -8.7664 24.566 9.11633" width="24.566pt" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink"><g transform="matrix(.013,0,0,-0.013,0,0)"><path d="M381 665C170 665 44 498 44 318C44 125 188 -15 369 -15C552 -15 703 117 703 333C703 534 550 665 381 665ZM359 629C491 629 601 517 601 306C601 114 502 21 390 21C249 21 146 158 146 346S248 629 359 629Z"></path></g><g transform="matrix(.013,0,0,-0.013,9.594,0)"><path d="M729 650H468V622C546 615 554 610 554 527V365H213V527C213 610 221 616 297 622V650H38V622C120 616 128 611 128 527V123C128 39 120 34 40 28V0H303V28C221 34 213 40 213 123V322H554V123C554 39 546 34 460 28V0H728V28C647 34 639 39 639 123V527C639 610 647 615 729 622V650Z"></path></g><g transform="matrix(.013,0,0,-0.013,19.552,0)"><path d="M320 255C320 327 260 385 186 385S52 327 52 255S112 125 186 125S320 183 320 255Z"></path></g></svg> scavenging assay were analyzed by the BCA model. The overlapping section was the common peaks shard by HM, WE, and HR.</div>

Journal of Analytical Methods in Chemistry

fig7

Figure 7

Figure 7: A Novel Strategy for Screening Active Components in <i>Cistanche tubulosa</i> Based on Spectrum-Effect Relationship Analysis and Network Pharmacology 

Figure 7 | A Novel Strategy for Screening Active Components in Cistanche tubulosa Based on Spectrum-Effect Relationship Analysis and Network Pharmacology 